Study wrapper · #214
Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue.
Editor's note
A preclinical mouse study of the growth-hormone/IGF-1 axis in diabetes, in which ipamorelin is used as a diagnostic stimulus rather than as a treatment under test. In streptozotocin-diabetic and non-diabetic mice, a single intravenous dose of ipamorelin provoked a much larger growth-hormone spike in the diabetic animals (150 vs 62 microg/L), yet their IGF-1 stayed low and did not rise — a picture of growth-hormone hypersecretion combined with growth-hormone resistance at the liver, mirroring features of human type 1 diabetes. The authors argue the diabetic mouse may model the human GH/IGF-1 disturbance better than the diabetic rat. Ipamorelin's role here is as a reliable GH-releasing probe, confirming it engages the axis; the study is not evaluating any ipamorelin benefit. These are rodent findings about disease physiology. For readers, the takeaway is contextual and mechanistic; no efficacy, safety, or dosing implications for people follow, and human data would be needed for any clinical claim.
Plain-language abstract
This study in mice examined how diabetes disturbs the growth-hormone system, using ipamorelin as a tool to trigger growth-hormone release. Female mice were made diabetic with a chemical (streptozotocin) or left non-diabetic, then given an injection of ipamorelin or saline. Blood was sampled before and 10 minutes after, and the liver was analysed for genes and proteins linked to growth hormone and to IGF-1 (a hormone growth hormone normally stimulates). After ipamorelin, diabetic mice released far more growth hormone than non-diabetic mice (150 versus 62 micrograms per litre). But despite this surge, the diabetic mice had low IGF-1 that did not rise, and their livers did not respond normally to growth hormone — a state of both too much growth hormone and resistance to it. The researchers said this pattern resembles human type 1 diabetes and that diabetic mice may model it better than diabetic rats. Ipamorelin was used only to provoke growth-hormone release. The study describes disease biology in mice and does not test whether ipamorelin helps any condition in people; human research would be needed.